Trends in Inflammatory Bowel Disease Therapy 1999

The proceedings of a symposium organized by AXCAN PHARMA, held in Vancouver, BC, August 27¿29, 1999
2000
ISBN: 978-0-7923-8762-6
Verlag: Springer Netherlands

Buch, Englisch, 262 Seiten, HC runder Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 1270 g

This Trends in Inflammatory Bowel Disease Therapy Symposium was held in Vancouver, British Columbia, Canada, 27~29 August 1999. This is the seventh international symposium, sponsored by Axcan Pharma Canada Inc., since the first symposium in 1986. The Canadian Association of Gastroenterology has co-sponsored these symposia since 1990. Each symposium has been published, and reflects and updates the extensive research and education, and the understanding of the mechanisms and treatment of inflammatory bowel disease. From the beginning, Canadian and international experts have been involved, maintaining a consistently high quality, both in their presentations, during discussions, and the subsequent publication of their work. There have been major advances since the symposium held two years ago, and these are presented in this book. In keeping with modern educational practice, objectives are provided, and all presentations were subject to written independent evalu­ ation. All participants are asked to declare any conflicts of interest. MOCOMP and educational credits are available.

Zielgruppe

Research

Autoren/Hrsg.

Williams, C. Noel

Bursey, R. F.

Gall, D. G.

Wallace, J. L.

Martin, F.

McLeod, R. S.

Sutherland, L. R.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Gastroentereologie, Proktologie

Inhaltsverzeichnis

Section I: Genetics.- 1 Genetics of Inflammatory bowel disease: where are we?.- 2 Genetics of inflammatory bowel disease: why is it important?.- 3 Genetics of IBD: impact on immune function.- Section II: Pathogenesis.- 4 Bacterial factors in inflammatory bowel disease pathogenesis.- 5 Inflammatory bowel disease: autoimmunity or chronic inflammation?.- 6 Neutrophil—epithelial interactions, and efforts to down-regulate them, in inflammatory bowel disease.- 7 Understanding inflammatory bowel disease at the millennium: tentative answers and future questions.- Section III: Clinical Challenges in Inflammatory Bowel Disease.- 8 Diagnosis of inflammatory bowel disease: an update.- 9 Recent developments in the diagnosis and management of paediatric inflammatory bowel disease.- 10 Inflammatory bowel disease in the elderly.- Section IV: Current Therapy in Inflammatory Bowel Disease.- 11 Induction of remission in ulcerative colitis.- 12 Remission maintenance in ulcerative colitis.- 13 Induction therapy for Crohn’s disease.- 14 Maintenance of remission in Crohn’s disease.- Section V: Bone Disease in Inflammatory Bowel Disease.- 15 Risk factors and prevalence of bone disease in inflammatory bowel disease.- 16 Management of low bone mass in patients with inflammatory bowel disease.- 17 Steroid-induced osteonecrosis in inflammatory bowel disease: Canadian legal status.- Section VI: Alternative Therapy.- 18 Psychotherapy for inflammatory bowel disease: new prospects.- 19 The use of complementary and alternative medicine by patients with inflammatory bowel disease.- 20 Gut inflammation: is there a role for herbal medicines?.- 21 The role of nutrition in the treatment of inflammatory bowel disease.- Section VII: New Therapeutic Approaches.- 22 Antibodies to proinflammatorycytokines.- 23 Immunomodulation of Crohn’s disease.- 24 Application of recombinant DNA technology to the identification of novel therapeutic targets in inflammatory bowel disease.- 25 The use of probiotics in inflammatory bowel disease.